Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Jan 6;139(1):134-137.
doi: 10.1182/blood.2021014232.

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

Alexis Maillard  1 , Rabah Redjoul  2 , Marion Klemencie  3 , Hélène Labussière Wallet  4 , Amandine Le Bourgeois  5 , Maud D'Aveni  6 , Anne Huynh  7 , Ana Berceanu  8 , Tony Marchand  9 , Sylvain Chantepie  10 , Carmen Botella Garcia  11 , Michael Loschi  12 , Magalie Joris  13 , Cristina Castilla-Llorente  14 , Anne Thiebaut-Bertrand  15 , Sylvie François  3 , Mathieu Leclerc  2 , Patrice Chevallier  5 , Stephanie Nguyen  1
Affiliations
Observational Study

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

Alexis Maillard et al. Blood. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Antispike response by risk factors associated with immunization after 2 vaccine doses. Serologic response to a 2-dose vaccination according to main factors associated with immunization after dose 2 (identified in multivariate analysis; see text and supplemental Tables 3 and 4). (A) Antispike antibody level. The violin plots contain interior box plots with upper and lower horizontal edges the 25th and 75th percentiles of antibody level and middle line the 50th percentile. The shape of the violin plots shows the smoothed probability density of the data. (B) Proportion of detectable antispike antibodies with 95% CI. The positivity threshold was given by the manufacturer for each used serological assay as detailed in supplemental Materials.
Figure 2
Figure 2
Antibody response after a third dose of SARS-CoV-2 vaccine. Antibody response before and after the third dose (D3). (A) Antibody levels (in BAU/mL) after the second and third dose of vaccine. Dots represent individual values and are filled according to the response after dose 2 (red for no response and blue for response weak response [<50 BAU/mL]). Antibody level significantly increased after dose 3 (P < .001, Mann-Whitney U test). (B-C) Antibody qualitative response to the third dose classified according antibody levels among patients with no (B) or weak (C) prior detectable response. “No” for undetectable response, “weak” for response <50 BAU/mL, and “good” for response ≥250 BAU/mL. The positivity threshold was given by the manufacturer for each used serological assay as detailed in supplemental Materials. D2, dose 2.
See this image and copyright information in PMC

References

    1. Ljungman P, de la Camara R, Mikulska M, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35(10):2885–2894. - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. COVE Study Group Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. - PMC - PubMed
    1. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661–662. - PMC - PubMed
    1. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204–2206. - PMC - PubMed

MeSH terms